Effect of nitazoxanide on qPCR seronegativity in patients infected with SARS-CoV-19

Authors

  • Luis Giovanni Rosales Pichardo Facultad de Medicina, Universidad Autónoma del Estado de México (UAEMex)
  • Miriam Deyanira Rodríguez Piña Facultad de Medicina, Universidad Autónoma del Estado de México (UAEMex)
  • Lissette Larissa Suarez Valencia Facultad de Medicina, Universidad Autónoma del Estado de México (UAEMex)
  • Hugo Mendieta Zerón Facultad de Medicina, Universidad Autónoma del Estado de México (UAEMex)

Abstract

Currently, the gold standard for the diagnosis of SARS-CoV-2 infection is RT-PCR (reverse transcriptase PCR). In addition to its diagnostic function, it is an indirect indicator of the viral load that a patient has. Our knowledge of this new virus indicates that a high viral load is associated with a worse prognosis and a more severe clinical picture. Therefore, achieving a decrease in said load can improve the prognosis of patients.

To this end, nitazoxanide is a therapeutic alternative that has the potential to reduce viral load. A retrospective observational study was carried out where, at the beginning of the study, a control qPCR (real-time PCR) was performed to later administer 500 mg of nitazoxanide to the participants every six hours for 7 days, after which the qPCR was repeated. The results were contrasted and analyzed, observing a negative result in 55.55% of the participants, it remains to determine molecularly with viral counts the real percentage of nitazoxanide for the seronegativity of the test.

Key words: COVID-19, nitazoxanide, qPCR, SARS-CoV-2.

Published

05-08-2024

How to Cite

Rosales Pichardo, L. G., Rodríguez Piña , M. D., Suarez Valencia , L. L., & Mendieta Zerón, H. (2024). Effect of nitazoxanide on qPCR seronegativity in patients infected with SARS-CoV-19. Revista Ciencias De La Salud Y Educación Médica , 4(5), 2–7. Retrieved from https://revistas.unan.edu.ni/index.php/Salud/article/view/4291

Issue

Section

Artículos Originales